- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07448753
ACTG2/FLNA Testing Yield in Adult Idiopathic Chronic Intestinal Pseudo-Obstruction (CIPO) With Reduced/Absent Distal Esophageal Contractility (CIPO_GEN)
March 3, 2026 updated by: Marina Coletta
Diagnostic Yield of ACTG2 and FLNA Gene Assessment in Adult Patients With Idiopathic Chronic Intestinal Pseudo-Obstruction and Reduced or Absent Distal Esophageal Contractility
To assess the diagnostic yield of Sanger sequencing for ACTG2 and FLNA genes evaluation on blood or saliva sample in patients with idiopathic CIPO in which high-resolution esophageal manometry (HRM) shows reduced (DCI <450 mmHg*s*cm) or absent distal esophageal contractility.
Study Overview
Status
Enrolling by invitation
Conditions
Study Type
Observational
Enrollment (Estimated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20122
- Ospedale Maggiore Policlinico di Milano
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Study participants will be selected from adult CIPO patients referred to and followed at our tertiary referral center during the study period.
Description
Inclusion Criteria:
- Age ≥ 18 years
- Male or female
- Primary chronic intestinal pseudo-obstruction (CIPO)
- Reduced (DCI < 450 mmHg·s·cm) or absent distal esophageal contractility on high-resolution manometry (HRM)
Exclusion Criteria:
- Secondary CIPO
Primary CIPO due to an autoimmune/inflammatory disorder, evidenced by the presence of any of the following antibodies:
- anti-Hu
- anti-GAD
- ASMA
- anti-gAChR
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The prevalence of mutations of ACTG2 or FLNA genes in a subgroup of patients with idiopathic CIPO with a myopathic phenotype revealed by reduced or absent distal esophageal contractility evaluated with high resolution esophageal manometry
Time Frame: October 2025-October 2026
|
October 2025-October 2026
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 17, 2025
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
January 30, 2027
Study Registration Dates
First Submitted
February 25, 2026
First Submitted That Met QC Criteria
February 25, 2026
First Posted (Actual)
March 4, 2026
Study Record Updates
Last Update Posted (Actual)
March 5, 2026
Last Update Submitted That Met QC Criteria
March 3, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID 6328- 6328_17.09.2025_P_bis
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pseudo Obstruction
-
University of NottinghamNorthern Care Alliance NHS Foundation Trust; Cambridge University Hospitals... and other collaboratorsRecruiting
-
Jinling Hospital, ChinaCompletedChronic Intestinal Pseudo ObstructionChina
-
MovetisCompletedChronic Intestinal Pseudo-ObstructionUnited Kingdom
-
Alfasigma S.p.A.CompletedChronic Intestinal Pseudo-obstructionBelgium, Italy, Spain
-
International University of Health and WelfareNot yet recruitingChronic Intestinal Pseudo-obstructionJapan
-
University Hospital, GrenobleRecruiting
-
Centre Hospitalier Universitaire de NiceActive, not recruitingSmall Bowel Obstruction | Intestinal Pseudo-ObstructionFrance
-
Shanghai 10th People's HospitalCompletedFecal Microbiota Transplantation | Intestinal Pseudo-ObstructionChina
-
Yokohama City UniversityASKA Pharmaceutical Co., Ltd.Active, not recruitingChronic Intestinal Pseudo-obstructionJapan
-
University of FloridaCompletedIleus | Small Bowel Obstruction | Ogilvie SyndromeUnited States